HBsAg脉冲的树突状细胞对CIK细胞功能的影响

目的探讨HBsAg脉冲的树突状细胞(DC)对细胞因子诱导的杀伤细胞(C IK)增殖和杀伤作用的影响。方法选择慢性乙肝患者27例,分离外周血单个核细胞(PBMC),经HBsAg脉冲后,用3H-TdR掺入法检测该细胞对C IK细胞增殖的刺激作用,用乳酸脱氢酶释放法检测特异性C IK细胞对HepG2.2.15细胞的特异性杀伤作用。结果HBsAg脉冲的DC对C IK细胞的增殖具有刺激作用。由HBsAg脉冲的DC所诱导的特异性C IK细胞对HepG2.2.15细胞的特异性杀伤作用增强。结论HBsAg脉冲的DC可增强C IK细胞的杀伤活性。     

病历中检验单的HBsAg和HBV DNA检测

目的　调查保存在传染病医院信息科内的病历中检验申请单被HBV污染情况及其是否具有传染性。方法　随机抽取我院信息科内近 30年的病历 15 0份 ,按每间隔期 10年分为 3组 ,每组 5 0份 ,取每份病历中的检验申请单 ,用标准固体表面HBV采样法取样 ,ELISA法检测HBsAg ,斑点杂交法检测HBVDNA。结果　近 30年的病历中的检验申请单有 16 %～ 5 2 %被HBsAg污染、2 %～ 2 4 %被HBVDNA污染 ;病历保存的时间越长 ,其中的检验申请单HBsAg、HBVDNA检出率越低 (P <0 .0 5 )。结论　传染病医院病历中有相当数量的检验申请单被HBV污染 ,有一定的传染性     

胎盘滋养细胞凋亡在HBV宫内感染中的作用研究

目的探讨乙型肝炎病毒（HBV）体外感染人绒膜滋养细胞株JEG-3后对细胞凋亡水平的影响,明确HBV感染胎盘的可能机制。方法用人HBVDNA＋血清体外感染JEG-3,免疫组化和WesternBlot检测细胞内HBVX抗原（HBxAg）的表达;用Annexin—V荧光素探针标记细胞表面的Ps磷脂酰丝氨酸,利用流式细胞仪检测早期细胞凋亡,碘化丙啶（PI）检测中晚期细胞凋亡。结果HBV体外感染人绒癌细胞株JEG-3后,细胞内检测到HBxAg的表达;细胞的早期凋亡率和晚期凋亡率明显降低。流式细胞仪AnnexinV＋PI双染方法检测细胞凋亡状态,HBV血清感染组细胞的早期凋亡水平和晚期凋亡水平均低于正常人血清对照组（t值分别为3．27、2．01,均P〈0．05）,差异均有统计学意义。结论HBV体外感染人绒癌细胞株JEG-3可表达HBxA2,从而抑制了细胞的早期凋亡及晚期凋亡;其是HBV感染胎盘的可能机制。     

大学生HBsAg生活接触传播的历史队列研究

病毒性乙型肝炎是一种严重危害人类健康且传播途径较广的传染病 ,我国成人乙型肝炎表面抗原 (HBsAg)阳性率为7%～ 1 0 %。HBsAg携带者不但分布广泛 ,多数不易转阴 ,且携带时间久 ,可长达 40多年。如此众多的携带者对健康人群的危害 ,已构成了严重的公共卫生问题。大学生是比较特殊的人群 ,入校后以寝室为单元 ,寝室成员之间日常生活接触十分密切。为探讨乙型肝炎病毒 (HBV)在大学生日常生活接触中传播情况 ,笔者进行了此项研究 ,现将结果报道如下。1　对象与方法1 .1　对象　以某高校共同生活 2年的学生为研究对象 ,应用历史队列研究方…     

HBV相关慢加急性肝衰竭患者血清HBsAg水平与HBV DNA水平及病情严重程度的关系

目的 探讨HBV相关慢加急性肝衰竭(ACLF)患者血清HBsAg水平与HBV DNA水平及病情严重程度的关系.方法 选取慢性乙型肝炎(CHB)患者119例(CHB组)和ACLF患者98例(ACLF组).采用罗氏电化学发光法检测血清HBsAg和HBeAg,荧光定量PCR法检测血清HBVDNA水平.分别比较两组不同HBeAg状态患者的HBsAg和HBV DNA水平差异以及HBsAg和HBV DNA水平的相关性.结果 ACLF组和CHB组患者血清HBeAg阴性患者分别占68.4％(67/98)和42.9％(51/119),差异有统计学意义(P＜0.01).ACLF组血清HBV DNA水平与CHB组比较差异无统计学意义(P＞0.05),两组血清HBeAg阳性患者HBV DNA均高于同组血清HBeAg阴性患者(P＜0.05).ACLF组血清HBsAg水平在血清HBeAg阳性和阴性患者间比较差异无统计学意义(P＞0.05),但均高于CHB组血清HBeAg阳性患者(P＜0.05).血清HBeAg阳性患者血清HBsAg与丙氨酸氨基转移酶、天冬氨酸氨基转移酶具有相关性(P＜0.05),血清HBeAg阴性患者血清HBsAg与血清HBV DNA水平及生化指标无显著相关性(P＞0.05).不同HBV DNA水平ACLF患者中不同HBsAg水平患者的比例比较差异无统计学意义(P＞0.05).结论 HBV相关ACLF患者血清HBsAg水平与HBV DNA水平及病情的严重程度无直接平行关系.     

大学生中HBsAg阳性者的心理障碍及干预

慢性乙型病毒性肝炎是由乙肝病毒引起严重危害人们身心健康的一种传染病。我国是乙肝高发国家，约有1．2亿乙肝病毒携带者，随着求职、升学、结婚、献血、入伍、饮食及健康体检，HB—sA。阳性被及时发现。由于其发病率高，病情迁延不愈，目前尚无特效药物治疗，因此，无论对乙肝病毒携带者还是对健康人，进行相关知识的健康教育都是十分必要的。笔者从预防保健工作中了解到，乙肝病毒携带者普通存在一定的心理障碍，经给予疏导和心理干预，均能得到满意的效果，其表现如下：     

HBsAg弱阳性标本乙肝标志物的检测分析

<正>目前,许多科室把HBsAg是阳性还是阴性作为初步判断是否感染乙肝病毒的指标,血站也用HBsAg来筛选献血者。测定HHsAg最常用的方法是ELISA法,一般酶标比色常以CO值0.105作为阴阳性判定的临界值,即标本A≥0.105为阳性,A<0.105为阴性。我科室将呈色介于阴阳性对照孔之间,A值0.075-0.135的标本称为弱阳性标本。笔者对来我院体检的200例HBsAg弱阳性标本的乙肝标志物进行检测,并对相关乙肝标志物模式及其临床意义作出初步分析。     

慢性乙肝患者HBsAg水平与HBV-DNA相关性研究

目的 探讨未经抗病毒治疗慢性乙肝患者不同病程HBsAg水平变化及其与HBV-DNA水平的相关性,为慢性乙肝感染干预治疗提供参考依据。方法 根据病程不同阶段,将2013年1月～2015年1月所收集的380例样本血清分为免疫耐受期（immune tolerance phase,IT）89例、免疫清除期（immune clearance phase,IC）82例、e抗原阴性肝炎期（hepatitis B e antigen negative,ENH）70例、低复制期（low-replicative phase,LR）92例、肝硬化（liver cirrhosis,LC）47例,使用微粒子化学发光法检测HBsAg值、酶比色法测定AST/ALT值,荧光定量PCR检测HBV-DNA,比较不同分组HBsAg水平及其与HBV-DNA的相关性。结果 慢性HBV感染不同阶段HBsAg水平中位数不同,IT（4.95 log10IU/ml）、IC（4.46 log10IU/ml）、ENH（2.96 log10IU/ml）、LR（3.22 log10IU/ml）、LC（2.87 log10IU/ml）差异有统计学意义（P<0.001）。不同病程ALT（P<0.001）、AST（P<0.001）、HBV-DNA水平（P<0.001）、基因型B/C分布（P=0.038）差异具有统计学意义。在IT期（r_s=0.482,P=0.004）、IC期（r_s=0.734,P<0.001）和ENH期（r_s=0.545,P<0.001）,HBsAg在不同分期与DNA水平呈正相关、HBsAg水平与年龄、ALT、AST之间未见相关性。结论 不同病程阶段的HBV感染,HBsAg水平有明显差异,临床诊断及治疗方案应结合不同指标的动态变化合理调整。     

HBIG抑制HBsAg、HBV DNA分泌的体外实验研究

目的研究乙型肝炎免疫球蛋白（HBIG）对肝细胞的跨膜转运作用和对乙型肝炎病毒（HBV）感染细胞模型的乙型肝炎表面抗原（HBsAg）、HBVDNA分泌的抑制作用。方法用含HBIG的培养基培养QSG7701细胞，在不同时间点定量检测培养上清的抗HBs，计算HBIG的透过率；用含HBIG的培养基培养HepG2．2．15细胞数天，或先以，定浓度的HBIG共培养，第3天后更换为不含HBIG的培养基继续培养细胞。于不同时间点定量检测培养上清的HBsAg、HBV DNA；用MTT比色试验观察药物的细胞毒性。结果浓度为0.1～0.4IU／mL的HBIG与QSG7701细胞共孵育48h时，细胞内约有38％～46％的HBIG。浓度为0．1～10.0IU/mL的HBIG作用第3、6．9天时能抑制HepG2，2．15细胞培养上清中HBsAg、HBV DNA的分泌（P〈0．01）。住尤药物继续培养的第5、7天，培养卜清中HBsAg浓度较有药物培养的第3天低且继续下降（P〈0．01），第9～11天逐步增高；培养上清HBV DNA水平在第5天时也较有药物培养的第3天低并继续下降（P〈0．01），第7～11大时逐步增高。结论在体外细胞实验中，HBIG能跨膜转运入肝细胞内，细胞内外的HBIG能抑制HBsAg、HBV DNA的分泌。     

“a”决定簇变异对慢性乙型肝炎患者HBsAg与HBsAb表达的影响

目的研究＂a＂决定簇变异对慢性乙型肝炎患者乙型肝炎表面抗原（HBsAg）与表面抗体（HBsAb）表达的影响。方法收集HBsAg阳性持续6个月以上的CHB患者866例，其中789例（91．1％）仅HBsAg阳性，77例（8．9％）患者血清HBsAg与HB-sAb均阳性。从77例血清HBsAg与HBsAb双阳患者中，选择14例血清HBsAg与HBsAb双阳患者为Ⅰ组。789例HBsAg阳性患者中随机选择12例HBsAg单独阳患者为Ⅱ组对照。对HBsAg编码基因进行扩增和克隆，每例样本至少克隆15个后进行测序分析。结果Ⅰ组患者S蛋白氨基酸残基改变数量为Ⅱ组患者的2．7倍[9．52变化量／100残基vs2．43变化量／100残基（9．52％VS2．43％），P〈0．01]，且绝大多数发生在主亲水区（MHR）“a”决定簇。MHR区至少出现2残基改变的在Ⅰ组有10例（71％），Ⅱ组3例（25％）。Ⅰ组患者S蛋白残基改变常见位点为s145、s129、s126、s144和s123。这些S基因位点突变，最终形成病毒的免疫逃逸。结论CHB患者HBsAg和HBsAb共存可能与“a”决定簇变异率升高相关。“a”决定簇变异可能为乙型肝炎病毒免疫逃逸突变的一种选择。HBV免疫逃逸对疫苗接种免疫效应、临床疾病诊断和治疗策略革新等有影响。     

polyI:C诱导人胎盘滋养层细胞抗HBV感染的体外研究

目的:探讨体外polyI:C对人胎盘滋养层细胞乙型肝炎病毒(HBV)感染的作用。方法:将2μg或8μg HBV重组质粒pcDNA3.1(+)-HBV1.3转染人胎盘滋养层细胞Bewo,12 h后以Toll样受体3(TLR3)配体polyI:C处理3天,同时设对照组。采用微粒子酶免疫分析法(MEIA)和荧光定量PCR法分别检测细胞上清液HBsAg、HBeAg及HBV DNA水平,并以荧光定量RT-PCR和ELISA分别检测细胞TLR3 mRNA表达及细胞上清IFN-β水平。结果:与对照组比较,polyI:C均可显著抑制Bewo细胞HBV复制(P<0.01或0.05),但与2μg HBV重组质粒转染组比较,转染8μg HBV重组质粒组polyI:C对HBV复制的抑制率显著下降(P<0.01),且polyI:C诱导Bewo细胞TLR3 mRNA表达及IFN-β水平显著下降,差异有统计学意义(P<0.05)。结论:polyI:C可诱导人胎盘滋养层细胞抗HBV感染,但随着HBV感染量的增大,通过下调细胞TLR3 mR-NA表达及IFN-β产生,其抗HBV感染的作用被显著削弱。     

山东省丁型肝炎病毒感染调查研究

为了解山东省丁型肝炎病毒感染状况 ,并探讨丁型肝炎病毒 ( HDV)感染与乙型肝炎病毒 ( HBV)感染的关系 ,应用酶联免疫吸附试验 ( EL ISA)对山东省 2 681例乙型肝炎病毒感染者进行了血清丁型肝炎病毒抗体 (抗 - HDV)检测 ,共检出抗 - HDV阳性者 2 0 7例 ,阳性率 7.72 %。HBs Ag携带者组抗 - HDV阳性率 3.16% ,乙肝患者组抗 - HDV阳性率 13.15% ,两组之间的差异有非常显著性 ( P<0 .0 0 1)。在乙肝患者组中 ,慢性活动性肝炎患者和重症肝炎患者抗 - HDV阳性率高于急性肝炎患者和慢性迁延性肝炎患者 ,差异有非常显著性 ( P<0 .0 0 1) ,表明乙肝病史越长、病情越重 ,其抗 - HDV阳性率越高。提示乙肝患者联合或重叠感染 HDV与乙肝慢性化和病情加重的形成有关。     

Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile

Chronic hepatitis B (CHB) virus infection, causing immune dysfunction and chronic hepatitis, is one of the leading risk factors for hepatocellular cancer. We investigated how Arthrospira affected hepatitis B surface antigen (HBsAg) reduction in CHB patients under continued nucleos(t)ide analogues (NA). Sixty CHB patients who had been receiving NA for at least one year with undetectable HBV DNA were randomized into three groups: control and oral Arthrospira at 3 or 6 g daily add-on therapy groups. Patients were followed up for 6 months. Oral Arthrospira-diet mice were established to investigate the possible immunological mechanism of Arthrospira against HBV. Within 6 months, mean quantitative HBsAg (qHBsAg) decreased in the oral Arthrospira add-on therapy group. Interestingly, interferon gamma (IFN-γ) increased but TNF-α, interleukin 6 (IL-6), hepatic fibrosis, and steatosis decreased in the add-on groups. In mice, Arthrospira enhanced both innate and adaptive immune system, especially natural killer (NK) cell cytotoxicity, B cell activation, and the interleukin 2 (IL-2), IFN-γ immune response. Arthrospira may modulate IL-2- and TNF-α/IFN-γ-mediated B and T cell activation to reduce HBsAg. Also, Arthrospira has the potential to restore immune tolerance and enhance HBsAg seroclearance in CHB patients through promoting T, B, and NK cell activation.     

大兴区2004.6～2006.6卫生从业人员体检结果分析

目的：了解大兴区食品和公共场所从业人员HBsAg阳性携带的状况，更好地为食品和公共场所的卫生监督提供依据。方法：取受检者静脉血，ALT采用全自动生化分析仪速率法，HBsAg采用酶联免疫吸附试验（ELISA）。结果：大兴区企业单位参加2004．6～2006．6年度健康体检的食品和公共场所从业人员共44182人，HBsAg阳性总检出率为2．05％，行业之间有显著性差异，食品卫生行业的检出率明显高于公共场所（食品行业占73．2％，公共场所占26．8％）；性别之间也有显著性差异，男性明显高于女性（男性占53．8％，女性占46．2％）；属地之间有显著性差异，外地人口明显高于北京本地（外地人口占84．8％，北京本地占15、2％）；各年龄组之间也有显著性差异，尤其以21岁以下的小年龄组HBsAg阳性检出率较高；单纯ALT异常总检出率为1．96％，行业之间有显著性差异，食品卫生行业的检出率明显高于公共场所（食品行业占61．8％，公共场所占38．2％）；性别之间也有显著性差异，男性明显高于女性（男性占80．9％，女性占19．1％）；属地之间有显著性差异，外地人口高于北京本地（外地人口占57．9％，北京本地占42．1％）；各年龄组之间也有显著性差异，尤其以21岁以上的大年龄组单纯ALT异常检出率较高。年度之间无显著性差异。结论：加强宣传力度，使食品生产经营单位和每一个食品从业人员为了自己和人民群众的身体健康，重视并坚持每年进行的健康检查。     

体外活化TLR3对HBV宫内感染新生儿免疫状况的影响

目的:通过体外活化Toll样受体3(TLR3),探索将Poly I:C(免疫佐剂)作为TLR3配体提高HBV宫内感染者TLR3蛋白含量,进而通过改变HBV宫内感染者DCs细胞及B细胞百分比,提供改善机体免疫状态的可能性。方法:采用面对面问卷调查方法连续收集152对HBsAg阳性孕妇及其新生儿流行病学资料,并采集新生儿脐血及股静脉血。分别采用酶联免疫吸附试验(ELISA)及实时荧光定量PCR检测新生儿出生24 h内外周血乙肝病毒标志物及HBV DNA含量,密度梯度离心法分离脐血单个核细胞(CBMCs)以进行体外培养,经HBV与Poly I:C刺激后,流式细胞术(FCM)检测新生儿CBMCs的TLR3蛋白含量及DCs细胞、B细胞的百分比。结果:HBV非宫内感染的TLR3蛋白含量在经HBV以及PolyI:C+HBV后呈现下降趋势。而HBV宫内感染组呈现先下降后升高的趋势。HBV非宫内感染组与宫内感染组CBMCs经PolyI:C+HBV刺激活化后,两组TLR3蛋白含量、mDC、pDC比例差异均无统计学意义(t=0.11,P=0.91;t=0.46,P=0.64;t=0.21,P=0.23);而两组B细胞百分比差异有统计学意义(t=2.36,P=0.02)。HBV宫内感染组经Poly I:C+HBV刺激后与非宫内感染组经HBV刺激后的B细胞百分比比较差异亦有统计学意义(t=2.45,P=0.02)。结论:Poly I:C作为免疫佐剂一定程度上提高HBV宫内感染者的TLR3蛋白水平,使宫内感染组的TLR3蛋白水平逐渐接近于非宫内感染组,进而改变CBMCs中DCs细胞及B细胞百分比含量,为改善HBV宫内感染新生儿的免疫状况使其接近非宫内感染者水平提供可能。     

国产重组乙型肝炎疫苗(中国仓鼠卵巢细胞)免疫后1～8年效果观察

目的观察新生儿接种国产重组乙型肝炎(乙肝)疫苗[中国仓鼠卵巢细胞(CHO细胞)]后1~8年免疫效果。方法2005年9~10月在4个试点乡对1997~1999年出生的儿童全部采集血清标本,检测乙肝病毒表面抗原(HBsAg)、乙肝病毒表面抗体(抗-HBs)和乙肝病毒核心抗体(抗-HBc)。结果免疫后1~8年,抗-HBs阳性(S/N≥2.1)率平均为91.95%,有效抗-HBs阳性(S/N≥10.0)率为75.74%,抗体S/N值几何平均浓度(GMC)为30.14毫国际单位/毫升。总的趋势是抗体阳性率和GMC随免疫年限延长逐渐降低。HBsAg阳性率为0.67%,抗-HBc阳性率为1.39%,未见HBsAg随免疫年限延长而逐渐升高的现象。结论国产重组乙肝疫苗(CHO细胞)免疫后1~8年抗体持久性下降,但保护效果良好。     

Monitoring the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children: Protective anti-HBs levels and cellular immune responses

Vaccination against hepatitis B virus (HBV) is recommended worldwide. The aim of this study was to assess the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children in the context of protective anti-HBs levels and cellular immune responses. Using a random questionnaire survey, 1695 pre-school children were recruited as research subjects during January 2015 to June 2017. Blood samples were obtained to measure HBV serological markers as well as peripheral immunocytes. The children were divided into non-, low- and hyper- responsive groups (NR, LR, and HR) based on the vaccination efficacy. Additionally, the effect of revaccination on the NR group was evaluated at 1 month after completion of the vaccination course. Among a total of 1695 children, 1591 (93.86%) were infants who were followed while undergoing their primary course of hepatitis B vaccination at the 0-1-6 month schedule, and 1249 (79.30%) of them developed antibodies against HBsAg (anti-HBs) titers greater than 10 IU/L. The results of immunocyte studies indicated that the CD8⁺ T cells, CD4⁺CD45RO⁺ T cells, CD8⁺CD45RA⁺ T cells, and T follicular helper (Tfh) cells increased significantly in NR compared with HR. However, lymphocytes, CD4⁺ T cells, and CD4⁺CD45RA⁺ T cells in NR were lower than that in HR. 96 of the non-response cases showed seroprotection after revaccination among 103 cases. Therefore, most of the preschool children who received hepatitis B vaccine in infancy achieved significant seroprotection. Seroconversion rates of individuals revaccinated after initial vaccination failure were significantly higher than those after primary vaccination. Different vaccination efficacy groups showed significant changes in circulating immunocytes, which might be a factor affecting the recombinant HBV vaccine’s immune effectiveness.     

Ending risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: A mathematical modelling study

BackgroundRisk-group HBV vaccination for men who have sex with men (MSM) was introduced in the Netherlands in 2002, followed by universal infant vaccination in 2011, that will enable termination of risk-group vaccination over time. The introduction of pre-exposure prophylaxis (PrEP) for HIV prevention might result in increased HBV testing and vaccination against HBV. The aim of this study was to investigate the impact of the transition from risk-group to universal HBV vaccination, accounting for improvements in HBV testing and treatment, as well as the introduction of PrEP.MethodsWe developed a mathematical model for HBV transmission among MSM. Universal vaccination was modelled by assigning some MSM (5–15% in 2028 increasing to 80–90% in 2033 and thereafter) to be vaccinated when they become sexually active. We investigated different scenarios assuming 0.5% extra vaccination rate and 0.5% extra testing rate due to PrEP consultations; and 5% of HIV-negative MSM on PrEP, that will reduce the probability of HBV acquisition by 88%.ResultsUniversal vaccination resulted in a reduction of 24% (interquartile range; 22–25%) of the total number of HBV infections among MSM estimated to occur from 2020 to 2070. With universal vaccination, terminating risk-group vaccination in 2030 or 2040 resulted in 30% or 10% more HBV infections over 2020–2070, respectively, compared to continuation of risk-group vaccination until 2070. With PrEP and continued risk-group vaccination, the total number of HBV infections over 2020–2070 was reduced by 13%.ConclusionsUniversal HBV vaccination can lead to a major reduction in HBV incidence among MSM in the future. The reduction becomes smaller when ending risk-group HBV vaccination, but larger by PrEP use for HIV prevention. Efforts to keep high levels of HBV vaccination, testing, and treatment have to be continued in the coming decades in order to eliminate HBV as a health threat for MSM.     

Differential activation of host cell signalling pathways through infection with two variants of influenza A/Puerto Rico/8/34 (H1N1) in MDCK cells

In cell culture-based influenza vaccine production, few efforts have been undertaken to characterise virus–host cell interactions in detail. Two influenza virus strains that grew to different virus titres, and differed in virus dynamics, apoptosis induction and proteome changes were observed.     

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease

BackgroundHepatitis B virus (HBV) infection remains a significant global burden, especially for patients with chronic kidney disease (CKD) receiving hemodialysis. Three doses of HepB–CpG (HEPLISAV-B® vaccine) induced a superior immune response compared with 4 double doses of HepB–Eng (Engerix-B®) in a phase 3 trial (HBV-17) in adults with CKD. Here we report the long-term immunogenicity and safety of HepB-CpG and HepB–Eng in eligible participants of HBV-17 who enrolled in this optional 34-month follow-up trial (HBV-19).MethodsHBV-19 is a multicenter, open-label, phase 3b trial of adults with CKD who previously received a complete series of HepB-CpG or HepB-Eng in the HBV-17 trial. Participants were assigned to seroprotection categories at enrollment on the basis of their antibody response to hepatitis B surface antigen (anti-HBs) in HBV-17. The objective was to evaluate the durability of seroprotection (defined as an anti-HBs concentration ≥ 10 mIU/mL) induced by HepB-CpG and HepB-Eng. Participants whose anti-HBs concentration was below 10 mIU/mL received additional HepB-CpG or HepB-Eng doses.Results147 participants were enrolled; 66.7 % were men, median age was 65.0 years, and 83.7 % were white. The durability of seroprotection in participants with CKD was similar in those who received HepB-CpG and those who received HepB-Eng. Antibody concentrations ≥ 100 mIU/mL persisted for longer in HepB-CpG than HepB-Eng recipients, among those with anti-HBs ≥ 100 mIU/mL post vaccination. The geometric mean anti-HBs concentration in the HepB-CpG group was significantly higher than in the HepB-Eng group over time (P ≤ 0.0001). The safety profiles were similar between the vaccine groups.ConclusionsDue to the higher antibody levels induced by HepB-CpG in participants with CKD, seroprotection against HBV may be expected to persist longer than that induced by HepB-Eng. ClinicalTrials.gov: NCT01282762.